RT Journal Article SR Electronic T1 Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy JF Journal for ImmunoTherapy of Cancer JO J Immunother Cancer FD BMJ Publishing Group Ltd SP 44 DO 10.1186/s40425-017-0243-4 VO 5 IS 1 A1 Sacha Gnjatic A1 Vincenzo Bronte A1 Laura Rosa Brunet A1 Marcus O. Butler A1 Mary L. Disis A1 Jérôme Galon A1 Leif G. Hakansson A1 Brent A. Hanks A1 Vaios Karanikas A1 Samir N. Khleif A1 John M. Kirkwood A1 Lance D. Miller A1 Dolores J. Schendel A1 Isabelle Tanneau A1 Jon M. Wigginton A1 Lisa H. Butterfield YR 2017 UL http://jitc.bmj.com/content/5/1/44.abstract AB As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system against cancer have led to breakthroughs for a variety of malignancies, success is limited to a subset of patients. Pre-existing immunological features of both the host and the tumor may contribute to how patients will eventually fare with immunotherapy. A broad understanding of baseline immunity, both in the periphery and in the tumor microenvironment, is needed in order to fully realize the potential of cancer immunotherapy. Such interrogation of the tumor, blood, and host immune parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. To approach these opportunities for progress, the Society for Immunotherapy of Cancer (SITC) reconvened the Immune Biomarkers Task Force. Comprised of an international multidisciplinary panel of experts, Working Group 4 sought to make recommendations that focus on the complexity of the tumor microenvironment, with its diversity of immune genes, proteins, cells, and pathways naturally present at baseline and in circulation, and novel tools to aid in such broad analyses.Abbreviations:CTLCytotoxic T lymphocyte(s)CTLA-4Cytotoxic T lymphocyte-associated protein 4CyTOFCytometry by time-of-flightDCDendritic cell(s)DFSDisease-free survivalFDAFood and Drug AdministrationGWASGenome-wide association studyIDOIndoleamine 2,3-dioxygenaseIHCImmunohistochemistryIVDMIAIn vitro diagnostic multivariate index assayMDSCMyeloid-derived suppressor cell(s)MHCMajor histocompatibility complexMSIMicrosatellite instabilityNGSNext-generation sequencingNKNatural killerNSCLCNon-small cell lung cancerOSOverall survivalPD-1Programmed cell death protein 1PD-L1Programmed death ligand 1PFSProgression-free survivalPMNPolymorphonuclearSITCSociety for Immunotherapy of CancerSNPSingle nucleotide polymorphism(s)TCRT cell receptorTfhFollicular helper T cell(s)ThHelper T cell(s)TILTumor-infiltrating lymphocyte(s)TLSTertiary lymphoid structure(s)TMETumor microenvironmentTregRegulatory T cell(s)